Barry Snow described the results of the study as a "Rubiks Cube" where understanding how the results came about is a puzzle. That is what they are trying to do now, looking at all the characteristics of the individual patients and seeing if it has any relationship to the responses at a given dose. The longer the study time, the more data points they have, the better the chances they have of getting some insight.
Personally I don't believe they will pursue the PD use of NTcell if they cannot find some reasonable good scioentific evidence of efficacy in the data from the trial over 18-24 months. They would need to see a consistent trend which leads to statistical significance to seek and allocate more funds.
- Forums
- ASX - By Stock
- 1AI
- AGM
AGM, page-183
Featured News
Add 1AI (ASX) to my watchlist
|
|||||
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.18M |
Open | High | Low | Value | Volume |
0.9¢ | 1.0¢ | 0.9¢ | $2.066K | 207.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 523973 | 0.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.0¢ | 713611 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 523973 | 0.009 |
24 | 7549358 | 0.008 |
9 | 6905133 | 0.007 |
7 | 2497250 | 0.006 |
4 | 2300000 | 0.005 |
Price($) | Vol. | No. |
---|---|---|
0.010 | 713611 | 2 |
0.011 | 941482 | 7 |
0.012 | 2037193 | 6 |
0.013 | 934768 | 4 |
0.014 | 70000 | 1 |
Last trade - 15.47pm 29/07/2024 (20 minute delay) ? |
Featured News
1AI (ASX) Chart |